

Cardiorenal Assessment Advanced Tests

AXINON® lipoFIT® • AXINON® GFR(NMR)

CE-labeled IVD (EU)

Two tests can help improve accuracy of cardiovascular and renal assessments — both key indicators of overall metabolomic function.


The AXINON® lipoFIT® for cardiovascular risk assessment and AXINON® GFR(NMR) for renal function measurement use the AXINON® System, our core technology platform. This system incorporates advanced diagnostic testing algorithms into highly accurate nuclear magnetic resonance (NMR) spectroscopy.

Numares Health

Discoveries for more accurate results


Cardiovascular: lipoFIT®

- Determines how many lipoprotein particles are in a sample, and what size they are, in addition to cholesterol concentration.
- Provides more specific measurement when LDL-c and LDL-p are discordant, often occurring in patients with metabolic diseases, like diabetes.



Renal: GFR(NMR)

- Combines two novel biomarkers, valine and myo-inositol, with creatinine and cystatin C.
- Improves accuracy: More closely correlates with mGFR than standard eGFR equations.
- Overcomes bias: Accounts for non-renal factors, including comorbidities, race, age, BMI and muscle mass.



Current standard tests. Here's what they miss.

Cardiovascular


- About 50% of patients hospitalized for coronary artery disease show normal LDL-c levels. This current standard lipid testing doesn't accurately capture risk.
- It doesn't provide specifics about cholesterol or lipoprotein subclasses (quantity, particle size, etc.), a better risk indicator.
- Comorbidities can mask actual risk by confounding the results.

Renal

- 30-year-old eGFR test measures one biomarker, creatinine.
- The result is so inaccurate the federal government required all US transplant centers to re-evaluate kidney transplant waitlists using a less biased assessment.
- eGFR doesn't account for comorbidities, race, age, BMI or muscle mass.

AXINON® System

- Innovative testing modality: Uses distinct, AI-enabled algorithms to identify and quantify multiple biomarkers.
- Specific biomarker measurement provides increased accuracy.
- Automated: Runs hundreds of samples a day with just one hour of lab employee time.



For more information, contact Dan Lindsay:
+1 818.606.4125 or Dan.Lindsay@numares.com

RENAL SELECTED PUBLICATIONS

Meeusen J, Stämmler F, Dasari S, et al. (2022). *Front. Med.* 9:988989.
Fuhrmann M, Santamaria A, Scott, R, et al. (2022). *Diagnostics* 2022, 12(5), 1120.
Stämmler F, Grassi M, Meeusen JW, et al. (2021). *Diagnostics (Basel)*. 2021 Dec 7;11(12):2291.
Ehrich J, Dubourg L, Hansson S, et al. (2021). *Diagnostics (Basel)*. 2021 Feb 3;11(2):234.

CARDIOVASCULAR SELECTED PUBLICATIONS

El Harchaoui, K., et al., *J Am Coll Cardiol*, 2007. 49(5): p. 547-53.
Sachdeva A, et al., *Am Heart J* 2009. 157:111-117 e2.
Mora, S., et al., *Circulation*, 2014. 129(5): 553-61.
Garber AJ, et al., *Endocr Prac* 2015. 21:438-47.
Jacobson TA, et al., *J Clin Lipidol* 2015. 9:129-69

www.numares.com



©2024 numares AG. AXINON® is a registered trademark of numares AG. All rights reserved.